Longevity Biotech Funding & AI Genomics
Key Questions
What was the total funding raised by longevity biotech companies in Q1 2026?
Longevity biotech pulled in $3.74B in Q1 2026, representing a 56% increase year-over-year. This surge included 173 AI-discovered drugs now in clinical trials. The broader market is projected to reach $8T with $8.5B invested overall in 2024.
Which companies recently raised funding in the longevity and AI genomics space?
Rejuvenate Bio raised $6M for gene therapy in companion animals, while NewLimit secured $435M in Series C funding now valuing it at $3.1B. Other raises include Everlab at $65M, Gero at $17M, ARTAN Bio at $1M seed, and Retro at a $1.8B valuation.
How is AI being applied to drug discovery and aging research?
AI is accelerating drug discovery with trillion-molecule screening and timelines projected to 2035, alongside WGS+AI insights. Eli Lilly's $2.75B AI bet shows 70% of AI-identified anti-aging candidates extending lifespan in animals. Human Longevity also launched a foundation using $599 WGS+AI for insights.
What role are billionaires and big pharma playing in longevity biotech?
Billionaires like Bezos, Altman, Zuckerberg, and Armstrong have driven $8.49B in investments through entities such as Altos, Retro, Biohub, and NewLimit. Big pharma deals include Novartis with BioAge and Lilly backing NewLimit, with Novo Nordisk linking semaglutide to longevity via biological age reduction.
Are there new institutional or grant programs supporting aging biology research?
The EU EIC is launching a €30M Pathfinder Challenge for biology of aging, offering up to €4M in non-dilutive grants. This adds to ecosystem support like VitaDAO governance for ARTAN Bio and multi-million-dollar AI foundation model deals.
Rejuvenate Bio raised $6M for gene therapy in companion animals, partnered with Merck Animal Health. Retro $1.8B valuation; Immortal Dragons $40M fund; Rapalogix $9.08M; AI timelines to 2035, WGS+AI, trillion-molecule screening. GLP-1 gene therapy one-time metabolic fix. Billionaire race: Bezos/Altos, Altman/Retro, Zuckerberg/Biohub, Armstrong/NewLimit – $8.49B in 2024. NewLimit raised $435M Series C (now $3.1B), backed by Eli Lilly and Founders Fund. Human Longevity launches Human Life Foundation with $599 WGS+AI insights. Multi-million-dollar deal with HLFM for AI foundation models. Big pharma deals: Novartis/BioAge, Lilly. $8.5B invested in 2024, market projected at $8T. Reid Hoffman left Microsoft board to focus on Manus, an AI drug discovery startup ($50M seed). Kakao Ventures invested in Tab Zero. Novo Nordisk CEO explicitly linking semaglutide to longevity, showing biological age reduction in heart/kidneys via protein clocks. Recent podcast interview with angel investor Nalina Murthy. Forbes piece (April 2026) reinforces billionaire pivot to longevity biotech. A market report on AI-accelerated drug discovery platforms. Eli Lilly's $2.75B AI bet on anti-aging drugs; 70% of AI-identified candidates extend lifespan in animals. New: Everlab raised $65M for AI-powered preventative healthcare platform. New: Gero raised $17M (total $34M) for AI-driven aging modeling, with Roche/Chugai ties. New: A video 'From AI to Anti-Aging: The Next Frontier of Venture Capital' covers VC funding for anti-aging biotech. New: EU EIC launching €30M Pathfinder Challenge targeting biology of aging with up to €4M non-dilutive grants—a significant institutional signal. New: Q1 2026 longevity biotech funding reached $3.74B, up 56% YoY, with 173 AI-discovered drugs in clinical trials, confirming accelerating investment. ARTAN Bio closed $1M seed round for suppressor tRNA platform with VitaDAO governance, adding to early-stage ecosystem. A practical report from Cannes 2026 on building longevity practices, including the emerging Chief Longevity Officer role, adds operational insight to the business side.